Biological
Lifileucel clinical trials
Also written LN-144.
- studies test it
- 24
- open now
- 11
- in phase 3
- 1
- first study started
- 2015
Keep track of what changes. Save the lifileucel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2024 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 10
- Phase 2
- 12
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 10
Who runs them
Industry 13 · Other 11
Iovance Biotherapeutics, Inc. (11) · Memorial Sloan Kettering Cancer Center (2) · Vastra Gotaland Region (2) · Shanghai Juncell Therapeutics (2) · Richard Wu (1) · University of Kansas Medical Center (1) · Abramson Cancer Center at Penn Medicine (1) · Karam Khaddour, MD, MS (1)
Often tested with
Tested in the same studies.
Autologous Tumor Infiltrating Lymphocytes LN-145 (13) · Pembrolizumab (4) · Interleukin-2 (3) · Cyclophosphamide (2) · Fludarabine (2) · Autologous Tumor Infiltrating Lymphocytes LN-145-S1 (2) · Melphalan (1) · Durvalumab (1)
Studies
Open first, then newest update. How each study uses lifileucel is read from its arms, and is right about nine times in ten.
Testing it · 24
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaRecruitingPhase 2Iovance Biotherapeutics, Inc.NCT07741877Written as Lifileucel
- Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.RecruitingPhase 3Iovance Biotherapeutics, Inc.NCT05727904Written as Lifileucel plus Pembrolizumab
- A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or AngiosarcomaRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05607095Written as Lifileucel (LN-144/LN-145)
- Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver MetastasesNot yet recruitingPhase 1Vastra Gotaland RegionNCT05903937Written as Autologous Tumor Infiltrating Lymphocytes
- A Phase Ib Study of GC101 in NSCLCRecruitingPhase 1Shanghai Juncell TherapeuticsNCT06473961Written as Autologous Tumor Infiltrating Lymphocytes
- A Phase II Study of GC101 in NSCLCRecruitingPhase 2Shanghai Juncell TherapeuticsNCT07560111Written as Autologous Tumor Infiltrating Lymphocytes
- PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced MelanomaNot yet recruitingEarly Phase 1Abramson Cancer Center at Penn MedicineNCT07700121Written as Lifileucel Infusion
- Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerRecruitingPhase 2Iovance Biotherapeutics, Inc.NCT04614103Written as LN-145
- TIL Therapy in cSCC and MCCRecruitingPhase 2Karam Khaddour, MD, MSNCT07288073Written as LN-145
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.RecruitingPhase 2Iovance Biotherapeutics, Inc.NCT06481592Written as Lifileucel
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver CancerRecruitingPhase 1Zhiyong HuangNCT06084299Written as Autologous Tumor Infiltrating Lymphocytes
- Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsTerminatedPhase 1Iovance Biotherapeutics, Inc.NCT06566092Written as LN-145/LN-144
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaActive, not recruitingPhase 2Iovance Biotherapeutics, Inc.NCT07288203Written as Lifileucel
- Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaTerminatedPhase 2Iovance Biotherapeutics, Inc.NCT03108495Written as LN-145
- A Study of LN-144 in People With Metastatic Melanoma to the BrainActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05640193Written as Lifileucel (LN-144)
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsTerminatedPhase 2Iovance Biotherapeutics, Inc.NCT03645928Written as Lifileucel
- Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic MelanomaCompletedPhase 2University of Kansas Medical CenterNCT06151847Written as Lifileucel
- Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaCompletedPhase 2Iovance Biotherapeutics, Inc.NCT02360579Written as Lifileucel
- Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma PatientsActive, not recruitingPhase 1Richard WuNCT05176470Written as Lifileucel
- Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver MetastasesCompletedPhase 1Vastra Gotaland RegionNCT04812470Written as Autologous Tumor Infiltrating Lymphocytes
See all 24 studies that test lifileucel →
As the comparator · 1 — what is tested is compared with lifileucel
Codes
What other systems call lifileucel · ClinicalTrials.gg INT017737
- UNII (FDA) R0835E18NHLIFILEUCELOne source FDA
- NCI Thesaurus C120552LifileucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R0835E18NH | LIFILEUCEL | One source FDA |
| NCI Thesaurus | C120552 | Lifileucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.